Cardiff Oncology Inc
Veridion Score
BETALOW CONF · 4/6 factorsComposite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.
- · Factor breakdown with raw signals
- · Day-over-day delta + driver
- · Factor coverage readout
- · Valuation · hype · market flow
- · Pro Chart event markers
- · Score history + alerts
Why is CRDF moving today?
Cardiff Oncology Inc is a clinical-stage biotechnology company advancing cancer treatments focused on PLK1 inhibition, a validated oncology target with practice-changing potential. Its main asset, onvansertib, is a specific, oral PLK1 inhibitor currently being evaluated in a Phase 2 trial for first-line treatment of RAS-mutated metastatic colorectal cancer (mCRC), addressing a large, underserved patient population with high unmet need. Onvansertib is also under investigation in other PLK1-driven cancers through ongoing investigator-initiated trials and has shown robust single agent clinical activity in hard-to-treat tumors. By targeting tumor vulnerabilities, to overcome treatment resistance and deliver improved clinical outcomes for patients.
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
CRDF overview
Related filings and maps
Congress activity in CRDF
No receipt-qualified Congressional disclosure is present for CRDF in the cached public ledger.
CRDF contract awards, year to date.
Public federal awards linked to this ticker.
CRDF lobbying filings, year to date.
Registered lobbying filings matched to Cardiff Oncology Inc.